血必净注射液用于ICU重症肺炎的疗效观察

Observation on Efficacy of Xuebijing Injection in Treatment of ICU Severe Pneumonia

目的:探讨血必净注射液用于重症加强护理病房(intensive care unit,ICU)重症肺炎患者的效果。方法:选取2015年10月—2016年10月湖北省公安县人民医院ICU收治的重症肺炎患者114例作为研究对象,按随机数字表法分成观察组和对照组,每组57例。对照组患者给予常规治疗,观察组患者在对照组基础上加用血必净注射液,比较两组患者的疗效、相关临床和炎症指标、急性生理及慢性健康评分(acute physiology and chronic health evaluationⅡ,APACHEⅡ)变化情况。结果:治疗后,观察组患者的总有效率为98.25%(56/57),明显高于对照组的82.46%(47/57),差异有统计学意义(P<0.05)。观察组患者的血氧饱和度、白细胞计数、氧分压(Pa O2)/吸入氧浓度、Pa O2、白细胞介素6、肿瘤坏死因子、超敏C反应蛋白明显低于对照组,差异均有统计学意义(P<0.05)。治疗7及14 d后,两组患者APACHEⅡ评分均较治疗前明显降低,且观察组降低程度明显优于对照组,差异均有统计学意义(P<0.05)。结论:血必净注射液用于ICU重症肺炎的效果较好,能有效缓解患者的临床症状,改善炎症指标及预后。

OBJECTIVE： To probe into the effects of Xuebijing injection in treatment of severe pneumonia in intensive care unit （ICU）. METHODS： 114 patients with severe pneumonia admitted into Hubei Gong an County People＇s Hospital from Oct. 2015 to Oct. 2016 were selected to be divided into observation group and control group via the random number table, with 57 cases in each. The control group was given conventional treatment, while the observation group additionally received Xuebijing injection based on the control group. The efficacy, changes of related clinical and inflammation indicators, acute physiology and chronic health evaluation Ⅱ （APACHE Ⅱ ） of two groups were compared. RESULTS： After treatment, the total effective rate of observation group was 98.25% （56/57）, significantly higher than that of control group [ 82.46% （47/57） ], with statistically significant difference （P 〈 0. 05 ）. The SaO2, WBC, PaO2/Fi02, PaO2, interlenkin-6, tumor necrosis factor and high-sensitivity C-reactive protein of observation group were lower than those of control group, with statistically significant difference （ P 〈 0. 05 ）. After treatment of 7 and 14 d, compared with before treatment, the APACHE Ⅱ score of two groups decreased significantly, and the observation group was better than the control group, with statistically significant difference （ P 〈 0. 05 ）. CONCLUSIONS ： The effects of Xuebijing injection in treatment of severe pneumonia in ICU is significant, which can effectively relieve the clinical symptoms, reduce the inflammation and improve patients＇prognosis.